- Novan Inc NOVN priced its previously announced public offering of 3.6 million shares at $11/share for gross proceeds of approximately $40 million.
- The offer price represents a 21% discount on the last close price of $13.85 on Wednesday. The offering will close by June 21.
- Underwriters have an option to purchase up to 545k additional shares.
- Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.
- Novan intends to use the net proceeds to fund the R&D of SB206, as well as for general corporate purposes.
- Last week, the company announced positive topline efficacy and safety results from the Phase 3 trial of SB206 for molluscum contagiosum.
- Price Action: NOVN shares are down 20.9% at $10.96 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
